Citigroup Maintains Sell on Integra Lifesciences, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch maintains a Sell rating on Integra Lifesciences and lowers the price target from $20 to $16.
October 01, 2024 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citigroup analyst Joanne Wuensch maintains a Sell rating on Integra Lifesciences and lowers the price target from $20 to $16.
The Sell rating and reduced price target from a major financial institution like Citigroup can negatively impact investor sentiment and lead to a decrease in the stock price of Integra Lifesciences in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100